Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
537
datasets available to search
ShareScore release 0.9.0
Dataset results
537 results for “Pharmaceuticals”
Establishment of a Personalized Pharmaceutical Plan in Renal or Hepatic Transplant Patients
ClinicalTrials.gov study NCT04295928. IPD Sharing: NO. Countries: 1. Publications: 1.
Pharmaceutical Care in Emergency Department
ClinicalTrials.gov study NCT01978925. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Pharmaceutical Collaborative Care Integrated to a Multidisciplinary Psychosocial Program
ClinicalTrials.gov study NCT02802371. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Individualized Pharmaceutical-care for Inpatients With Cancer Pain
ClinicalTrials.gov study NCT03455023. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Impact of a Pharmaceutical Care Model in the Management of Chronic Myeloid Leukemia Patients
ClinicalTrials.gov study NCT03090477. IPD Sharing: NO. Countries: 1. Publications: 6.
PRPP Model for Evaluation the Effect of Non-pharmaceutical Therapies
ClinicalTrials.gov study NCT01869712. IPD Sharing: Not stated. Countries: 1. Publications: 3.
The Impact of a Pharmaceutical Care Model on Improving Polycystic Ovary Syndrome
ClinicalTrials.gov study NCT04416620. IPD Sharing: NO. Countries: 2. Publications: 5.
Prevention of Pneumococcal Infections: Impact Collaborative Medico-pharmaceutical Care Structured to Improve Vaccination Coverage of Patients at Risk.
ClinicalTrials.gov study NCT05060146. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Optimized Medico-pharmaceutical Collaboration in the Drug Management of Patients With Heart Failure
ClinicalTrials.gov study NCT03902028. IPD Sharing: Not stated. Countries: 1. Publications: 9.
Data from: Simultaneous determination of diosmin and hesperidin in combined pharmaceutical preparation by synchronous fluorescence spectrofluorimetric method
Open the record for dataset details and reuse information.
Data from: Water-borne pharmaceuticals reduce phenotypic diversity and response capacity of natural phytoplankton communities
Open the record for dataset details and reuse information.
Green and sensitive spectrofluorimetric determination of two pharmaceutically important cephalosporin drugs in their dosage forms
Open the record for dataset details and reuse information.
Data for: Can pharmaceutical pollution alter the spread of infectious disease? A case study using fluoxetine.
Open the record for dataset details and reuse information.
Data from: Sharing of clinical trial data and results reporting practices among large pharmaceutical companies: cross sectional descriptive study and pilot of a tool to improve company practices
Open the record for dataset details and reuse information.
Efficient removal of pharmaceuticals from water using graphene nanoplatelets as adsorbent
Open the record for dataset details and reuse information.
Clinical Trial Transparency and Data-Sharing Among Bio-Pharmaceutical Companies and the Role of Company Size, Location, and Product Type: A Cross-Sectional Descriptive Analysis
Open the record for dataset details and reuse information.
Five years of pharmaceutical industry funding of patient organisations in Sweden: cross-sectional study of companies, patient organisations and drugs
<p><strong>Abstract</strong></p> <p><strong>Background:</strong> Many patient organisations collaborate with drug companies, resulting in concerns about commercial agendas influencing patient advocacy. We contribute to an international body of knowledge on patient organisation-industry relations by considering payments reported in the industry’s centralised ‘collaboration database’ in Sweden. We also investigate possible commercial motives behind the funding by assessing its association with drug commercialisation. </p> <p><strong>Methods:</strong> Our primary data source were 1,337 payment reports from 2014-2018. After extraction and coding, we analysed the data descriptively, calculating the number, value and distribution of payments for various units of analysis, e.g. individual companies, diseases and payment goals. The association between drug commercialisation and patient organisation funding was assessed by, first, the concordance between leading companies marketing drugs in specific diseases and their funding of corresponding patient organisations and, second, the correlation between new drugs in broader condition areas and payments to corresponding patient organisations.</p> <p><strong>Results: </strong>46 companies reported paying €6,449.224 (median €2,411; IQR €1,024-4,569) to 77 patient organisations, but ten companies provided 67% of the funding. Small payments dominated, many of which covered costs of events organised by patient organisations. An association existed between drug commercialisation and industry funding. Companies supported patient organisations in diseases linked to their drug portfolios, with the top 3 condition areas in terms of funding – cancer endocrine, nutritional and metabolic disorders; and infectious and parasitic disorders – accounting for 63% of new drugs and 56% of the funding.</p> <p><strong>Conclusion:</strong> This study reveals close and widespread ties between patient organisations and drug companies. Relatively few companies dominated the funding landscape by supporting patient organisations in disease areas linked to their drug portfolios. This commercially motivated funding may contribute to inequalities in resource and influence between patient organisations. The association between drug commercialisation and industry funding is also worrying because of the therapeutic uncertainty of many new drugs. Our analysis benefited from the existence of a centralised database of payments – which should be adopted by other countries too – but databases should be downloadable in an analysable format to permit efficient and independent analysis.</p>
SARS-CoV-2 non-pharmaceutical interventions in Brazilian municipalities
<p>Brazil has one of the fastest-growing COVID-19 epidemics worldwide. Non-pharmaceutical interventions (NPIs) have been adopted on a municipal level, with asynchronous actions taken across 5,568 municipalities and the Federal District. This paper addresses this complexity reporting on a novel dataset with survey responses from 4,027 mayors, 72.4% of the total municipalities in the country. This dataset responds to the urgency to track and share findings on fragmented policies to tackle health crises like the COVID-19 pandemic. Quantifying NPIs can allow for understanding the effectiveness of interventions in reducing transmission. We offer temporal details for a range of measures aimed at reducing social distancing as well as when local governments started to relax those measures.</p>
Figure 6 from: Sharmin S, Sohrab MH, Moni F, Afroz F, Rony SR, Akhter S (2020) Simple RP-HPLC method for Aceclofenac quantitative analysis in pharmaceutical tablets. Pharmacia 67(4): 383-391. https://doi.org/10.3897/pharmacia.67.e57981
Figure 6 Robustness Study (a) Variance of peak area for change in different method parameters with %RSD; (b) Variance of Retention time for change in different method parameters with %RSD. *Method was robust for change in pH of mobile phase (±0.5), wavelength (±3 nm) and column temperature (±3 °C).
Figure 6 from: Golembiovska О, Voskoboinik O, Berest G, Kovalenko S, Logoyda L (2021) Quality by design approach for simultaneous determination of original active pharmaceutical ingredient quinabut and its impurities by using HPLC. Message 1. Pharmacia 68(1): 79-87. https://doi.org/10.3897/pharmacia.68.e50704
Figure 6 Linear dependence of the theoretical concentration of quinabut on the found concentration in normalized coordinates.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.